1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PharmaCielo Ltd.

PharmaCielo Ltd.

PCLOF
PharmaCielo Ltd.US flagOther OTC
0.04
USD
+0.00
- -
8.08MMarket Cap
PharmaCielo Ltd.
PCLOF
(Other OTC)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2026
TTM
FRC
- -
- -
0.01
0.02
0.01
0.04
0.01
0.02
0.01
0.02
Revenue per Share
- -
-1.18
-0.36
-0.39
-0.18
-0.1
-0.1
-0.05
-0.02
-0.02
Basic EPS, GAAP
- -
-0.64
-0.37
-0.25
-0.15
-0.07
-0.03
-0.01
-0.02
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.23
0.48
0.46
0.19
0.13
0.04
-0.01
-0.04
-0.05
-0.05
Book Value per Share
0.23
0.48
0.44
0.19
0.13
0.04
-0.01
-0.04
-0.05
-0.05
Tangible Book Value per Share
- -
- -
96
113
146
151
160
171
188
194
Basic Weighted Avg Shares
- -
- -
1
3
2
5
2
3
3
4
Sales/Revenue/Turnover
- -
- -
-4,362.67
-1,635.17
-1,295.31
-215.4
-651.38
-140.87
-131.68
-87.56
Operating Margin (%)
- -
- -
1
2
1
2
1
1
1
1
Depreciation Expense
- -
- -
-35
-44
-27
-15
-16
-9
-4
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-4,405.55
-1,648.73
-1,369.14
-273.45
-1,057.09
-262.7
-141.06
-103.08
Profit Margin (%)
- -
- -
16
- -
1
-3
-18
-19
-20
-20
Working Capital
- -
- -
1
4
8
12
3
5
- -
- -
LT Debt
- -
- -
45
26
19
6
-2
-8
-11
-11
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
86.49
Return on Capital (%)
- -
-104.42
-151.88
-122.03
-116.87
-112.89
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Jun'27
ST Debt
16
16
18
LT Borrowings
4
5
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
170
176
211
Market Capitalization
31
13
13

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Jun'27
Total Current Assets
3
2
3
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
- -
- -
Inventories
2
2
2
Total Current Liabilities
23
21
23
Payables & Accruals
6
5
5
ST Debt
16
16
18
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
34.81%
46.12%
Free Cash Flow
- -
-10.64%
134.2%
Net Income, GAAP
- -
-35.43%
-60.86%
Sales/Revenue/Turnover
- -
34.77%
-27.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
1
1
1
- -
3
2027
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
-0.01
- -
- -
- -
-0.02
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Harrow Health, Inc. (HROW)
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
Sproutly Canada Inc. (SRUTF)
Cardiol Therapeutics Inc. (CRDL)
Gnomestar Craft Inc. (GNOM.CN)
Stemsation International, Inc. (STSN)
Business
PharmaCielo Ltd. and its affiliated entities specialize in the cultivation, rigorous processing, and global distribution of medical-grade cannabis products. The company focuses on producing high-purity cannabinoid extracts, including a diverse range of oils, distillates, and isolates for both CBD-dominant and THC-dominant applications, alongside dried cannabis flower. Beyond its core offerings, it provides white-label services for third-party brands and offers a telemedicine platform. PharmaCielo primarily serves health and wellness manufacturers, pharmaceutical companies, medical clinics, and cosmetic brands across international markets, including North America, Europe, and Latin America. Leveraging a vertically integrated model from Colombia, the company emphasizes sustainable cultivation and EU GMP-compliant production standards. Recent strategic initiatives include a partnership with Benuvia Operations for pharmaceutical-grade CBD API manufacturing and a supply agreement with Ease Labs for the São Paulo government in Brazil. PharmaCielo Ltd. maintains its corporate headquarters in Toronto, Canada.

Company News

Company News APIChatGPT

  • newsfilecorp.com

    PharmaCielo Announces 2026 First Quarter Results

  • newsfilecorp.com

    PharmaCielo Announces 2026 Year-End Results

  • newsfilecorp.com

    PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing

  • newsfilecorp.com

    PharmaCielo Announces Intention to Issue Interest Shares

  • newsfilecorp.com

    PharmaCielo Announces the Issuance of Interest Shares

  • newsfilecorp.com

    PharmaCielo Announces 2025 Q3 Results, AGM Details

  • feeds.newsfilecorp.com

    PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

  • newsfilecorp.com

    PharmaCielo Announces Revocation of FFCTO and Related Corporate Matters

  • globenewswire.com

    PharmaCielo Completes La Margarita Land Sale, Repays Banco Agrario Loan, Strengthens Balance Sheet, Completes Audit

  • newsfilecorp.com

    PharmaCielo Announces Issuance of Cease Trade Order

  • newsfilecorp.com

    PharmaCielo Reports Q4 2024 Financial Results

  • newsfilecorp.com

    PharmaCielo Announces Issuance of Shares for Settlement of Certain Amounts Owing

  • newsfilecorp.com

    PharmaCielo Reports Q3 2024 Financial Results

  • newsfilecorp.com

    PharmaCielo Announces Intention to Extend Expiry Date of Warrants

  • newsfilecorp.com

    PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024

  • newsfilecorp.com

    PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024

  • newsfilecorp.com

    CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading

  • newsfilecorp.com

    PharmaCielo Provides Update on Reinstatement for Trading

  • newsfilecorp.com

    PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023, and the First Quarter Ended March 31, 2024

  • newsfilecorp.com

    PharmaCielo Announces Issuance of Failure to File Cease Trade Order